

Published in final edited form as:

Angew Chem Int Ed Engl. 2013 June 24; 52(26): . doi:10.1002/anie.201302565.

A Highly Step-Economical Synthesis of Dictyostatin

Stephen Ho, Cyril Bucher, and Prof. James L. Leighton

Department of Chemistry, Columbia University, 3000 Broadway, New York, NY 10027, USA

James L. Leighton: leighton@chem.columbia.edu

Keywords

dictyostatin; total synthesis; step-economy; scalability; stereotriad

In 1994 Petit reported the isolation and anti-cancer activity of the marine sponge-derived macrolide dictyostatin.^[1] Wright subsequently isolated a sample that allowed initial biological characterization of dictyostatin as a potent inducer of tubulin polymerization,^[2] and that was used by Wright and Paterson to make a full structural assignment in 2004.^[3] This assignment was confirmed soon thereafter by total syntheses by Paterson^[4] and Curran,^[5] and the material thus obtained facilitated more detailed characterization of dictyostatin's mechanism of action.^[6,7] Total syntheses by Phillips^[8] and Ramachandran,^[9] formal syntheses by Micalizio^[10] and Cossy,^[11] a synthesis of C(9)-epi-dictyostatin by Gennari,^[12] second generation syntheses by Paterson^[13] and Curran,^[14] and several fragment syntheses^[15] followed these initial reports. In addition, the Paterson/Wright^[16] and Curran/Day^[17] teams have reported extensive SAR studies, while the Paterson/Díaz/Jiménez-Barbero^[18] and Curran/Snyder^[19] teams have advanced models for the interaction of dictyostatin with the taxane binding site on α -tubulin. Because dictyostatin and some of the prepared analogs are among the most potent microtubule-stabilizing agents characterized to date, there has been and continues to be intense interest in the possibility of advancing dictyostatin or an analog thereof into the clinic, a goal which might be facilitated by the development of a significantly more efficient and step-economical synthesis. As part of a larger program devoted to the development of new strategies and methods for the synthesis of complex and precious marine macrolides with high levels of step-economy, efficiency, and scalability,^[20] we have developed and report herein a synthesis of dictyostatin that comprises just 14 steps in the longest linear sequence.

Similarly to the previous syntheses of dictyostatin, our retrosynthesis disconnected the target into three roughly equally complex fragments, **1**, **2**, and **3** (Fig. 1A). It was in the synthesis of the fragments, and especially the C(12)-C(14) and C(20)-C(22) stereotriad-containing fragments **1** and **2** that we saw an opportunity for a streamlining of the synthesis. Ever since its introduction by Roush more than 20 years ago, what might be called the "Roche ester strategy" has reigned supreme for the synthesis of such stereotriads,^[21] and indeed was employed in the Paterson, Curran, and Ramachandran syntheses, in most of the approaches reported by others, and in most of the syntheses of the related natural product discodermolide.^[22] In this approach, the requisite enantiomer of the Roche ester is protected, reduced, and oxidized to the corresponding aldehyde, which is then subjected to diastereoselective crotylation, followed by several additional functional group manipulations (Fig. 1B). Thus, these stereotriad syntheses typically comprise at least 6–7 steps of which all

Correspondence to: James L. Leighton, leighton@chem.columbia.edu.

 Supporting information for this article is available on the WWW under <http://www.angewandte.org> or from the author.

but one are protecting group or redox reactions. The crotylation of a configurationally stable aldehyde such as **4** would represent an ideal alternative, but of course, no such aldehyde exists (Fig. 1C). Protected versions of **4** do exist, however, and can be prepared using Landis' ligand for asymmetric hydroformylation reactions.^[23] Given that hydroformylation reactions tend to be clean, we were optimistic that the crotylation reactions could be carried out in operationally simple one-pot procedures (Fig. 1D). After we began our investigations, Burke reported a similar sequence employing an ortho ester-protected acrylate, in which the product aldehyde was reacted *in situ* with *trans*-crotylpinacolboronate.^[24] This elegant demonstration of the power of the concept notwithstanding, significant work remained to establish whether externally controlled crotylations would work well with the products of the hydroformylation reactions and, more importantly, to establish whether and how these reactions could be easily and inexpensively scaled.

The synthesis of iodide **1** commenced with the rhodium-catalyzed hydroformylation of 2-vinyl-1,3-dioxolane with Landis' bis[(*R,R,S*)-DiazaPhos-SPE] ligand^[23] to produce aldehyde **5** (Scheme 1). At first, we employed Rh(acac)(CO)₂ and ligand loadings of 0.50 and 0.55 mol % respectively, according to Landis' original procedure, and these conditions produced **5** with 4.2:1 regioselectivity and in 92% ee. Because the ligand is far and away the most expensive component of the reaction, however, and because Sigma-Aldrich discontinued the sale of the ligand during the course of this project, we were highly motivated to investigate how low we could get the catalyst/ligand loadings and eventually settled on a loading of 0.015 mol %.^[25] This did result in a small drop in both regioselectivity (3.4:1) and ee (86%), but in terms of the amount of **5** produced per unit of ligand, this represented a truly significant increase in efficiency. Asymmetric crotylation of **5** using our recently reported and more easily scaled crotylsilane (*S,S*)-**6**^[26] was effectively carried out *in situ*, and this one-pot procedure resulted in the isolation of **7** in 62% yield. It is worth emphasizing again that because the starting dioxolane is relatively inexpensive, this yield figure is not particularly meaningful as a measure of the true efficiency of this reaction. It should be noted instead that this optimized procedure allowed the production of more than a gram of **7** using just 2 mg of the Landis ligand. Ozonolysis of **7** and subsequent Wittig reaction with stabilized ylide **8** could be rendered as a simple one-pot procedure and resulted in the isolation of **9** in 83% yield (10:1 *E:Z*). Alcohol-directed hydrogenation^[27] with Crabtree's catalyst^[28] proceeded highly diastereoselectively (20:1 dr) and led, after *in situ* alcohol silylation with *tert*-butyldimethylsilyl triflate (TBSOTf), to the isolation of **10** in 80% yield. Finally, ester reduction with DIBAL-H gave alcohol **11** (86% yield), which was converted to iodide **1** in 95% yield. This 5-step synthesis of **1** proved readily scalable and was used to prepare multi-gram amounts of both **11** and **1** in just a few weeks.

The synthesis of hydrazone **2** began in a similar fashion with the asymmetric hydroformylation of 2-methyl-2-vinyl-1,3-dioxolane (Scheme 2). Because this substrate is more hindered, the catalyst/ligand loading could not be reduced quite as much, but could nevertheless be effectively dropped to 0.030 mol %. These conditions resulted in the production of **12** with 1.1:1 regioselectivity and in 91% ee. Felkin-selective crotylation of aldehyde **12** with *trans*-crotylpinacolboronate **13** was highly diastereoselective (20:1) and was easily performed in one-pot in analogy to the Burke procedure.^[24] Once optimized, this sequence produced **14** in 51% yield (as above, we note that a more meaningful measure of the efficiency of this reaction is the fact that more than a gram of **14** may be produced using only 4 mg of the Landis ligand). On larger scales, however, we found it more convenient to chromatographically separate the aldehyde regioisomers prior to the crotylation reaction, both to avoid wasting large amounts of **13** and to avoid a more tedious separation of the crotylation products. Alcohol silylation with triethylsilyl triflate (TESOTf) proceeded smoothly to give **15** in 97% yield and was followed by ozonolysis to give aldehyde **16**.

Without further purification, **16** was subjected to the *cis*-selective diene synthesis using allylsilane **17** that was developed by Paterson as part of a discodermolide synthesis.^[29] Following *in situ* base-promoted Peterson elimination,^[30] HCl was added to hydrolyze the ethylene ketal and this resulted in TES ether hydrolysis as well, giving **18** in 65% overall yield from **15**. Resilylation with TESOTf was followed *in situ* by hydrazone formation to give **2** in 90% yield. This synthesis of **2** requires just 5 or 6 steps (depending on whether or not **12** is isolated) and allowed the preparation of more than 21 g of **2** in a campaign carried out by a single chemist in less than 3 weeks. Because this route required two separate silylations of the same alcohol, we have developed an alternative route: **14** may be directly subjected to ozonolysis, and the resulting aldehyde may be treated with Matteson's reagent (**19**)^[31] followed by *in situ* base-promoted Peterson elimination, to deliver **18** in 71% yield. This modification results in a 4 or 5 step synthesis of **2** and obviates the use of large amounts of CrCl₂ during scale-up.

The two most significant challenges in the synthesis of phosphonate **3** are the *cis*-dienoate and the Still-Gennari type phosphonate. The former task has typically required multi-step solutions, while the latter – due to the failure of tris(trifluoroethyl)phosphite to engage productively in Arbuzov reactions – has been accomplished by the (in our hands, technically difficult, capricious, and poorly scalable) addition of the metallated methyl phosphonate to an acid chloride at –100 °C. As described here, we have devised novel single step solutions for both of these challenges. Sc(OTf)₃-catalyzed crotylation^[32] of known (and commercially available) aldehyde **20**^[33] with (*S,S*)-**21**^[34] (with an HCl work-up optimized for ketal hydrolysis) gave ketone **22** in 86% yield and 91% ee (Scheme 3). Treatment of **22** with 2.1 equiv of TBSOTf both silylated the alcohol and converted the ketone into the corresponding TBS enol ether, and was followed by *in situ* silyl enol ether bromination with *N*-bromosuccinimide (NBS) to give bromoketone **23** in 80% yield. To get around the failure of tris(trifluoroethyl)phosphite to engage productively in Arbuzov reactions, we wondered whether it might be possible to first perform an Arbuzov reaction with a different phosphite, and then simply transesterify the product with trifluoroethanol. Indeed, we have reduced this idea to practice: **23** was subjected to an Arbuzov reaction with (PhO)₂POMe, and the resulting diphenylphosphonate was treated *in situ* with trifluoroethanol and DBU to give the desired Still-Gennari-type phosphonate **24** in 72% yield. Finally, a Pd(OAc)₂-catalyzed Heck reaction with *cis*-iodoacrylate **25** gave *cis*-dienoate **3** in 74% yield.^[35] This last reaction results in a significant improvement in step-economy and overall efficiency relative to, for example, the corresponding cross-coupling approach to the diennoate synthesis that requires pre-activation of the alkene coupling partner. Principally due to the development of the one-pot Arbuzov/transesterification reaction and the Heck approach to the *cis*-dienoate, this synthesis of **3** requires just 4 steps, and made possible the preparation of multi-gram quantities of **24** (we did not want to store large amounts of *cis*-dienoate **3** and made only what was necessary for the completion of the synthesis) in less than 2 weeks.

Fragment coupling and completion of the synthesis proceeded as described in Scheme 4. Deprotonation of hydrazone **2** with LDA under Evans' carefully designed hexane-free conditions^[36] and alkylation of the resultant metalloenhydrazone with iodide **1** gave **26** in 72% yield. Treatment of **26** with HF•pyridine in wet THF led to hydrolysis of the TES ether and the hydrazone to give **27** in 91% yield. Narasaka's *syn*-selective α -hydroxyketone reduction^[37] using Prasad's protocol^[38] proceeded highly diastereoselectively (20:1 dr) to give diol **28** in 91% yield. Selective silylation of the C(19) hydroxyl group with tri-*iso*-propylsilyl triflate (TIPSOTf) was followed *in situ* by silylation of the C(21) hydroxyl group with trimethylsilyl triflate (TMSOTf), which also resulted in acetal hydrolysis^[39] to produce aldehyde **29** in 82% yield. Still-Gennari olefination^[40] of **29** with phosphonate **3** proceeded with ~5:1 *Z:E* selectivity, and the desired *Z*-enone **30** (the C(21) TMS ether was hydrolyzed

in the workup) was isolated in 73% yield. Deprotection of the 2-(trimethylsilyl)ethyl (TMSE) ester was accomplished with tris(dimethylamino)-sulfonium difluorotrimethylsilicate (TAS-F)^[41] to deliver hydroxy acid **31**, which was directly subjected to the macrolactonization reaction without purification. Following Curran's demonstration of its superiority in this context,^[42] the macrolactonization was carried out using Shiina's protocol with 2-methyl-6-nitrobenzoic anhydride,^[43] and led to the isolation of macrolactone **32** in 61% yield over two steps from **30** and without significant isomerization of the C(2)-C(3) *Z*-alkene. Diastereoselective reduction of the C(9) ketone was accomplished using the CBS protocol with catecholborane^[44] and gave **33** in 80% yield. Finally, global silyl ether deprotection with unbuffered HF•pyridine delivered dictyostatin in 73% yield.

Our synthesis of dictyostatin proceeds with a longest linear sequence of 14 steps. Each of the 3 fragments (**1–3**) was prepared in just 4 or 5 steps, and this unrivalled step-economy was achieved through a combination of methodological and strategic innovation and the successful telescoping of steps into technically simple and effective one-pot procedures at several points in the route. The important innovations realized in the course of this project include the one-pot syntheses of stereotriads **7** and **14**, the one-pot Arbuzov/transesterification route to Still-Gennari-type α -ketophosphonate **24**, and the Heck approach to the synthesis of the C(1)-C(5) *cis*-dienoate. The ready scalability of the 3 fragment syntheses that accrued from this step-economy was amply demonstrated by the preparation of multi-gram quantities of each of them in just a few weeks or less. Should a dictyostatin analog emerge that merits clinical evaluation, we believe our synthesis could serve as the starting point for the development of a process that could deliver large amounts of each of the fragments with significantly reduced costs in terms of time, effort, and money. The step-economy of our synthesis, and more specifically the multi-gram quantities of the 3 fragments that we have been able to stockpile as a direct result, may also have the far more immediate and tangible benefit of greatly facilitating our own efforts to design and then rapidly synthesize analogs in pursuit of a clinical candidate.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was supported by a grant from the National Institute of General Medical Sciences (GM058133).

References

1. Pettit GR, Cichacz ZA, Gao F, Boyd MR, Schmidt JM. *J Chem Soc, Chem Commun.* 1994:1111–1112.
2. Isbrucker RA, Cummins J, Pomponi SA, Longley RE, Wright AE. *Biochem Pharmacol.* 2003; 66:75–82. [PubMed: 12818367]
3. Paterson I, Britton R, Delgado O, Wright AE. *Chem Commun.* 2004:632–633.
4. Paterson I, Britton R, Delgado O, Meyer A, Poullennec KG. *Angew Chem.* 2004; 116:4729–4733. *Angew Chem Int Ed.* 2004; 43:4629–4633.
5. Shin Y, Fournier JH, Fukui Y, Brückner AM, Curran DP. *Angew Chem.* 2004; 116:4734–4737. *Angew Chem Int Ed.* 2004; 43:4634–4637.
6. Buey R, Barasoain I, Jackson E, Meyer A, Giannakakou P, Paterson I, Mooberry S, Andreu JM, Díaz JF. *Chem Biol.* 2005; 12:1269–1279. [PubMed: 16356844]

7. Madiraju C, Edler MC, Hamel E, Raccor BS, Balachandran R, Zhu G, Giuliano KA, Vogt A, Shin Y, Fournier JH, Fukui Y, Brückner AM, Curran DP, Day BW. *Biochemistry*. 2005; 44:15053–15063. [PubMed: 16274252]
8. O'Neil GW, Phillips AJ. *J Am Chem Soc*. 2006; 128:5340–5341. [PubMed: 16620095]
9. Ramachandran PV, Srivastava A, Hazra D. *Org Lett*. 2007; 9:157–160. [PubMed: 17192109]
10. Shimp HL, Micalizio GC. *Tetrahedron*. 2009; 65:5908–5915.
11. Gallon J, Esteban J, Bouzbouz S, Campbell M, Reymond S, Cossy J. *Chem Eur J*. 2012; 18:11788–11797. [PubMed: 22865684]
12. Zanato C, Pignataro L, Ambrosi A, Hao Z, Trigili C, Díaz JF, Barasoain I, Gennari C. *Eur J Org Chem*. 2011:2643–2661.
13. Paterson I, Britton R, Delgado O, Gardner NM, Meyer A, Naylor GJ, Poullennec KG. *Tetrahedron*. 2010; 66:6534–6545.
14. Zhu W, Jiménez M, Jung WH, Camarco DP, Balachandran R, Vogt A, Day BW, Curran DP. *J Am Chem Soc*. 2010; 132:9175–9187. [PubMed: 20545347]
15. a) Prusov E, Röhm H, Maier ME. *Org Lett*. 2006; 8:1025–1028. [PubMed: 16524259] b) Jägel J, Maier ME. *Synlett*. 2006:693–696. c) Shaw SJ, Zhang D, Sunderman KF, Myles DC. *Synth Commun*. 2006; 36:1735–1743. d) Baba VS, Das P, Mukkanti K, Iqbal J. *Tetrahedron Lett*. 2006; 47:7927–7930. e) Sharon O, Monti C, Gennari C. *Tetrahedron*. 2007; 63:5873–5878. f) Saibaba V, Sampath A, Mukkanti K, Iqbal J, Das P. *Synthesis*. 2007:2797–2802. g) Dilger AK, Gopalsamuthiram V, Burke SD. *J Am Chem Soc*. 2007; 129:16273–16277. [PubMed: 18047348] h) Dias LC, Lima DJP, Gonçalves CCS, Andricopulo AD. *Eur J Org Chem*. 2009:1491–1494. i) Yadav JS, Rajender V. *Eur J Org Chem*. 2010:2148–2156. j) Ferreiro-Mederos L, Vila-Gisbert S, Urbano A, Carreño MC, Colobert F. *Org Biomol Chem*. 2011; 9:758–764. [PubMed: 21082125] k) Dias LC, Sant'Ana DP, Viera YW, Gonçalves CCS, Lima DJP. *J Braz Chem Soc*. 2012; 23:344–348.
16. a) Paterson I, Gardner NM, Poullennec KG, Wright AE. *Bioorg Med Chem Lett*. 2007; 17:2443–2447. [PubMed: 17336522] b) Paterson I, Gardner NM, Guzmán E, Wright AE. *Bioorg Med Chem Lett*. 2008; 18:6268–6272. [PubMed: 18951787] c) Paterson I, Gardner NM, Poullennec KG, Wright AE. *J Nat Prod*. 2008; 71:364–369. [PubMed: 18081257] d) Paterson I, Naylor GJ, Wright AE. *Chem Commun*. 2008:4628–4630. e) Paterson I, Gardner NM, Guzmán E, Wright AE. *Bioorg Med Chem*. 2009; 17:2282–2289. [PubMed: 19022679] f) Paterson I, Naylor GJ, Fujita T, Guzmán, Wright AE. *Chem Commun*. 2010; 46:261–263. g) Paterson I, Naylor GJ, Gardner NM, Guzmán E, Wright AE. *Chem-Asian J*. 2011; 6:459–473. [PubMed: 21254424]
17. a) Shin Y, Choy N, Turner TR, Balachandran R, Madiraju C, Day BW, Curran DP. *Org Lett*. 2002; 4:4443–4446. [PubMed: 12465908] b) Shin Y, Fournier JH, Balachandran R, Madiraju C, Raccor BS, Zhu G, Edler MC, Hamel E, Day BW, Curran DP. *Org Lett*. 2005; 7:2873–2876. [PubMed: 15987158] c) Fukui Y, Brückner AM, Shin Y, Balachandran, Day BW, Curran DP. *Org Lett*. 2006; 8:301–304. [PubMed: 16408900] d) Jung WH, Harrison C, Shin Y, Fournier JH, Balachandran R, Raccor BS, Sikorski RP, Vogt A, Curran DP, Day BW. *J Med Chem*. 2007; 50:2951–2966. [PubMed: 17542572] e) Shin Y, Fournier JH, Brückner AM, Madiraju C, Balachandran R, Raccor BS, Edler MC, Hamel E, Sikorski RP, Vogt A, Day BW, Curran DP. *Tetrahedron*. 2007; 63:8537–8562. [PubMed: 18728696] f) Jiménez M, Zhu W, Vogt A, Day BW, Curran DP. *Beilstein J Org Chem*. 2011; 7:1372–1378. [PubMed: 22043248]
18. Canales A, Matesanz R, Gardner NM, Andreu JM, Paterson I, Díaz JF, Jiménez-Barbero J. *Chem Eur J*. 2008; 14:7557–7569. [PubMed: 18449868]
19. Jogalekar AS, Damodaran K, Kriel FH, Jung WH, Alcaraz AA, Zhong S, Curran DP, Snyder JP. *J Am Chem Soc*. 2011; 133:2427–2436. [PubMed: 21299225]
20. a) Spletstoser JT, Zacuto MJ, Leighton JL. *Org Lett*. 2008; 10:5593–5596. [PubMed: 19007175] b) Harrison TJ, Ho S, Leighton JL. *J Am Chem Soc*. 2011; 133:7308–7311. [PubMed: 21524078] c) Chalifoux WA, Reznik SK, Leighton JL. *Nature*. 2012; 487:86–89. [PubMed: 22763452] d) Harrison TJ, Rabbat PMA, Leighton JL. *Org Lett*. 2012; 14:4890–4893. [PubMed: 22950417] e) Reznik SK, Marcus BS, Leighton JL. *Chem Sci*. 2012; 3:3326–3330. f) Reznik SK, Leighton JL. *Chem Sci*. 2013; 4:1497–1501.
21. Roush WR, Palkowitz AD, Ando K. *J Am Chem Soc*. 1990; 112:6348–6359.
22. Smith AB III, Freeze BS. *Tetrahedron*. 2008; 64:261–298. [PubMed: 21113402]

23. McDonald RI, Wong GW, Neupane RP, Stahl SS, Landis CR. *J Am Chem Soc.* 2010; 132:14027–14029. [PubMed: 20845958]
24. Risi RM, Burke SD. *Org Lett.* 2012; 14:2572–2575.
25. Wong GW, Adint TT, Landis CR. *Org Synth.* 2012; 89:243–254.
26. Suen LM, Steigerwald ML, Leighton JL. *Chem Sci.* 10.1039/C3SC50714A
27. Hoveyda AH, Evans DA, Fu GC. *Chem Rev.* 1993; 93:1307–1370.
28. a) Crabtree RH, Morris GE. *J Organomet Chem.* 1977; 135:395–403. b) Crabtree RH, Davis MW. *Organometallics.* 1983; 2:681–682. c) Crabtree RH, Morehouse SM. *Inorg Synth.* 1986; 24:173–176.
29. a) Paterson I, Schlapbach A. *Synlett.* 1995:498–500. b) Paterson I, Florence GJ, Gerlach K, Scott JP, Sereinig N. *J Am Chem Soc.* 2001; 123:9535–9544. [PubMed: 11572673]
30. Mickel SJ, Sedelmeier GH, Niederer D, Schuerch F, Seger M, Schreiner K, Daeffler R, Osmani A, Bixel D, Loiseleur O, Cercus J, Stettler H, Schaer K, Gamboni R, Bach A, Chen GP, Chen WC, Geng P, Lee GT, Loeser E, McKenna J, Kinder FR, Konigsberger K, Prasad K, Ramsey TM, Reel N, Repic O, Rogers L, Shieh WC, Wang RM, Waykole L, Xue S, Florence G, Paterson I. *Org Process Res Dev.* 2004; 8:113–121.
31. Tsai DJS, Matteson DS. *Tetrahedron Lett.* 1981; 22:2751–2752.
32. Kim H, Ho S, Leighton JL. *J Am Chem Soc.* 2011; 133:6517–6520. [PubMed: 21486033]
33. Kelly TR, Ananthasubramanian L, Bovah K, Gillard JW, Goerner RN, King PF, Lyding JM, Tsang WG, Vaya J. *Tetrahedron.* 1984; 40:4569–4577.
34. Hackman BM, Lombardi PJ, Leighton JL. *Org Lett.* 2004; 6:4375–4377. [PubMed: 15524487]
35. a) Lu X, Huang X, Ma S. *Tetrahedron Lett.* 1992; 33:2535–2538. b) Knowles JP, O'Connor VE, Whiting A. *Org Biomol Chem.* 2011; 9:1876–1886. [PubMed: 21283899]
36. Evans DA, Rieger DL, Jones TK, Kaldor SW. *J Org Chem.* 1990; 55:6260–6268.
37. Narasaka K, Pai FC. *Tetrahedron.* 1984; 40:2233–2238.
38. Chen KM, Hardtmann GE, Prasad K, Repic O, Shapiro MJ. *Tetrahedron Lett.* 1987; 28:155–158.
39. Fujioka H, Okitsu T, Sawama Y, Murata N, Li R, Kita Y. *J Am Chem Soc.* 2006; 128:5930–5938. [PubMed: 16637661]
40. Still WC, Gennari C. *Tetrahedron Lett.* 1983; 24:4405–4408.
41. Scheidt KA, Chen H, Follows BC, Chemler SR, Coffey DS, Roush WR. *J Org Chem.* 1998; 63:6436–6437.
42. Eiseman JL, Bai L, Jung WH, Moura-Letts G, Day BW, Curran DP. *J Med Chem.* 2008; 51:6650–6653. [PubMed: 18839939]
43. a) Shiina I, Ibuka R, Kubota M. *Chem Lett.* 2002:286–287. b) Shiina I, Kubota M, Ibuka R. *Tetrahedron Lett.* 2002; 43:7535–7539. c) Shiina I, Kubota M, Oshiumi H, Hashizume M. *J Org Chem.* 2004; 69:1822–1830. [PubMed: 15058924]
44. a) Corey EJ, Bakshi RK. *Tetrahedron Lett.* 1990; 31:611–614. b) Corey EJ, Helal CJ. *Angew Chem.* 1998; 110:2092–2118. *Angew Chem Int Ed.* 1998; 37:1986–2012.






Figure 1.


(A) Disconnection of dictyostatin into 3 fragments of similar complexity; (B) The “Roche ester strategy” for the synthesis of functionalized stereotriads; (C) A hypothetical one-step stereotriad synthesis from aldehyde **4**; (D) A proposal for the one-pot synthesis of the C(12)-C(14) and C(20)-C(22) stereotriads of dictyostatin.

**Scheme 1.**

An efficient synthesis of iodide **1** in just 5 steps. TBSOTf = *tert*-butyldimethylsilyl triflate, DIBAL-H = di-*iso*-butylaluminum hydride.

**Scheme 3.**

An efficient synthesis of phosphonate **3** in just 4 steps. DIBAL-H = di-*iso*-butylaluminum hydride, TBSOTf = *tert*-butyldimethylsilyl triflate, NBS = *N*-bromosuccinimide, DBU = 1,8-diazabicyclo[5.4.0]undec-7-ene, TFEOH = 2,2,2-trifluoroethanol, TMSE = 2-(trimethylsilyl)ethyl.



Scheme 4.

Fragment coupling and completion of the synthesis in 9 steps from **1** and **2**, and in 5 steps from **3**. LDA = lithium di-*iso*-propylamide, DMPU = 1,3-Dimethyl-3,4,5,6-tetrahydro-2(1*H*)-pyrimidinone, TIPSOTf = tri-*iso*-propylsilyl triflate, TMSOTf = trimethylsilyl triflate, NaHMDS = sodium hexamethyldisilazide, TAS-F = tris(dimethylamino)-sulfonium difluorotrimethylsilicate, DMAP = 4-dimethylamino pyridine.